Irinotecan (CPT-11)

N° de catalogueS1198 Lot :S119810

Imprimer

Données techniques

Formule

C33H38N4O6

Poids moléculaire 586.68 Numéro CAS 97682-44-5
Solubilité (25°C)* In vitro DMSO 25 mg/mL (42.61 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Ajouter les solvants au produit individuellement et dans l'ordre.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml signifie légèrement soluble ou insoluble.
* Veuillez noter que Selleck teste la solubilité de tous les composés en interne, et la solubilité réelle peut différer légèrement des valeurs publiées. Ceci est normal et est dû à de légères variations d'un lot à l'autre.
* Expédition à température ambiante (les tests de stabilité montrent que ce produit peut être expédié sans aucune mesure de refroidissement.)

Préparation des solutions mères

Activité biologique

Description Irinotecan est un inhibiteur de la topoisomérase I pour les cellules LoVo et HT-29 avec des IC50 de 15,8 μM et 5,17 μM, respectivement.
Cibles
Topo I
(LoVo, HT-29 cells)
In vitro Irinotecan is activated to SN-38 by carboxylesterases to become able to interact with its target, topoisomerase I. This compound induces similar amounts of cleavable complexes at its IC50 in LoVo cells and HT-29 cell lines. SN-38 induces a concentration-dependent formation of cleavable complexes, which is not significantly different in LoVo cells and HT-29 cell lines. Cell accumulation of this chemical is markedly different, reaching consistently higher levels in HT-29 cells than in LoVo cells. The lactone E-ring of this compound and SN-38 hydrolyses reversibly in aqueous solutions, and the interconversion between the lactone and carboxylate forms is dependent on pH and temperature. Liver is primarily responsible for the activation of this agent to SN-38. At equal concentrations of this drug and SN-38 glucuronide, the rate of beta-glucuronidase-mediated SN-38 production is higher than that formed from this compound in both tumour and normal tissue. It is also converted to SN-38 in intestines, plasma and tumor tissues. This agent is significantly more active in SCLC than in NSCLC cell lines, whereas no significant difference between histological types is observed with SN-38.
In vivo In COLO 320 xenografts, Irinotecan induces a maximum growth inhibition of 92%. A single dose of this compound significantly increases amounts of topoisomerase I covalently bound to DNA in stomach, duodenum, colon and liver. Concomitantly, the Irinotecan-treated group shows significantly higher amounts of DNA strand breaks in colon mucosa cells compared to the control group.
Caractéristiques Irinotecan est une prodrogue utilisée pour traiter le cancer colorectal métastatique.

Protocole (de référence)

Test cellulaire :

[1]

  • Lignées cellulaires

    LoVo and HT-29 cells

  • Concentrations

    0 μM -100 μM

  • Temps d'incubation

    48 hours

  • Méthode

    Exponentially growing cells (LoVo and HT-29 cells) are seeded in 20 cm2 Petri dishes with an optimal cell number for each cell line (2 × 104 for LoVo cells, 105 for HT-29 cells). They are treated 2 days later with increasing concentrations of Irinotecan or SN-38 for one cell doubling time (24 hours for LoVo cells, 40 hours for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the this compound or this chemical concentrations responsible for 50% growth inhibition as compared with cells incubated without this compound or this chemical.

Étude animale :

[5]

  • Modèles animaux

    Female nude mice with COLO 320 and WiDr xenografts

  • Posologies

    20 mg/kg

  • Administration

    Administered via i.p.

Références

  • https://pubmed.ncbi.nlm.nih.gov/11914913/
  • https://pubmed.ncbi.nlm.nih.gov/16842384/
  • https://pubmed.ncbi.nlm.nih.gov/15182436/
  • https://pubmed.ncbi.nlm.nih.gov/9649129/
  • https://pubmed.ncbi.nlm.nih.gov/9033637/
  • https://pubmed.ncbi.nlm.nih.gov/21046105/
  • https://pubmed.ncbi.nlm.nih.gov/16317751/

Validation du produit par le client

<p>In vitro cell uptake data showing the HA coating on HAC-PFP-DC nanoparticles significantly improves drug delivery into prostasphere and mammosphere cells enriched with CSCs. Fluorescence micrographs of mammosphere cells after incubated with the simple mixture of free DOX&CPT, PFP-DC nanoparticles, and HAC-PFPDC nanoparticles for 3 h at 37℃.</p>

, , Biomaterials, 2015, 72:74-89.

<p>Growth inhibitory effects of Irinotecan in human pancreatic cancer cells. Panc1 cells were plated in triplicates into 48-well plates at a density of 10,000 cells/ml. After 24 hours, complete culture medium was changed into fresh low-serum-containing medium (1% FBS) containing DMSO (control) or indicated doses of Irinotecan (Selleckchem). Cell viability 72 hours after treatment was determined by AlamarBlue assay (Invitrogen) according to manufacturer's instructions. Results are expressed as percentages of control, which was arbitrarily assigned 100% viability, and represented as the mean ± standard deviation (SD) of the tripicate wells. </p>

Dr. Edita Aksamitiene from Thomas Jefferson University, , Dr. Mikhail Menshikov of Cardiology Research Center

Selleck's Irinotecan (CPT-11) A été cité par 60 Publications

Identification of novel drug-specific PARP inhibitor resistance mechanisms in ovarian cancer-implications for clinical practice [ Br J Cancer, 2026, 135(2):290-302] PubMed: 41998207
Vitrification-based tissue-to-organoid cryopreservation workflow for colorectal cancer [ N Biotechnol, 2026, 93:341-350] PubMed: 42055114
Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model [ Oncol Rep, 2026, 55(1)9] PubMed: 41201043
A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy [ Cell Stem Cell, 2025, S1934-5909(25)00265-6] PubMed: 40812300
A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities [ Cell Rep Med, 2025, S2666-3791(25)00102-8] PubMed: 40147445
Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma [ J Exp Clin Cancer Res, 2025, 44(1):13] PubMed: 39810240
A Novel Modulator of Resistance for Oxaliplatin-Based Therapy for Colorectal Cancer: The ESCRT Family Member VPS4A [ Cells, 2025, 14(12)929] PubMed: 40558556
Homologous Repair-Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy [ United Eur Gastroent, 2025, 13(7):1328-1342] PubMed: 40823818
The Synergistic Effect of PARP Inhibitors and Irinotecan in Small Cell Lung Cancer Cells [ Cancer Res Treat, 2025, 10.4143/crt.2024.728] PubMed: 39788642
Proteomic profiling identifies upregulation of aurora kinases causing resistance to taxane-type chemotherapy in triple negative breast cancer [ Sci Rep, 2025, 15(1):3211] PubMed: 39863788

POLITIQUE DE RETOUR
La politique de retour inconditionnelle de Selleck Chemical garantit une expérience d'achat en ligne fluide à nos clients. Si vous n'êtes en aucun cas satisfait de votre achat, vous pouvez retourner tout article dans les 7 jours suivant sa réception. En cas de problèmes de qualité du produit, qu'il s'agisse de problèmes liés au protocole ou au produit, vous pouvez retourner tout article dans les 365 jours suivant la date d'achat initiale. Veuillez suivre les instructions ci-dessous lors du retour des produits.

EXPÉDITION ET STOCKAGE
Les produits Selleck sont transportés à température ambiante. Si vous recevez le produit à température ambiante, soyez assuré que le service d'inspection de la qualité de Selleck a mené des expériences pour vérifier que le placement à température normale pendant un mois n'affectera pas l'activité biologique des produits en poudre. Après réception, veuillez stocker le produit conformément aux exigences décrites dans la fiche technique. La plupart des produits Selleck sont stables dans les conditions recommandées.

NON DESTINÉ À UN USAGE HUMAIN, VÉTÉRINAIRE DIAGNOSTIQUE OU THÉRAPEUTIQUE.